Stockscreener 앱 받기
0.39
20.49%
-2.49
시간 외 거래:
.47
0.08
+20.51%
전일 마감가:
$2.88
열려 있는:
$0.41
하루 거래량:
4,948
Relative Volume:
66.00
시가총액:
$N/A
수익:
$496.00K
순이익/손실:
$-14.49M
주가수익비율:
-0.1403
EPS:
-2.78
순현금흐름:
$-11.45M
1주 성능:
-20.49%
1개월 성능:
+777.39%
6개월 성능:
+955.79%
1년 성능:
-20.17%
1일 변동 폭
$0.35
$0.41
1주일 범위
$0.35
$0.41
52주 변동 폭
$0.35
$0.41
Yield 10 Bioscience Inc Stock (YTEN) Company Profile
YTEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| YTEN | 0.39 | 0 | 496.00K | -14.49M | -11.45M | -2.78 |
| CTVA | 56.99 | 39.17B | 16.64B | 695.00M | 651.00M | 1.29 |
| NTR | 45.60 | 22.50B | 26.84B | 790.00M | 2.67B | 4.33 |
| CF | 87.38 | 15.07B | 5.98B | 1.16B | 1.82B | 10.75 |
| MOS | 25.81 | 8.22B | 12.19B | 244.80M | 465.00M | 6.33 |
| FMC | 55.23 | 6.86B | 4.17B | 1.46B | 493.00M | 3.93 |
Yield 10 Bioscience Inc Stock (YTEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-09-10 | 개시 | H.C. Wainwright | Buy |
| 2020-08-27 | 업그레이드 | National Securities | Neutral → Buy |
| 2019-11-18 | 다운그레이드 | National Securities | Buy → Neutral |
| 2019-05-31 | 재개 | Maxim Group | Buy |
| 2018-07-12 | 개시 | Maxim Group | Buy |
Yield 10 Bioscience Inc 주식(YTEN)의 최신 뉴스
3 Prominent Dividend Stocks With Up To 5.6% Yield - Simply Wall St
SEC Form 10-Q filed by Harvard Bioscience Inc. - Quantisnow
Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals - AccessWire
Yield10 Bioscience Delays Critical Asset Sale Vote Due to Low Shareholder Turnout | YTEN Stock News - StockTitan
Farm groups urge more flexibility for climate-smart practices in upcoming 45Z guidance - Agri-Pulse
Camelina Sativa Market Size and Growth Analysis: Rapid - openPR
9 Best Biotech Stocks Of November 2024 - Forbes
Chinese Dividend Stocks To Consider In October 2024 - Simply Wall St
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
Biopolymers Market to grow by USD 17.11 Trillion from 2024-2028, driven by crude oil price volatility, with AI influencing market trendsTechnavio - The Malaysian Reserve
Biopolymers Market To Grow By USD 17.11 Trillion From 2024-2028, Driven By Crude Oil Price Volatility, With AI Influencing Market TrendsTechnavio - MENAFN.COM
7 Best Pharmaceutical Stocks to Buy for Income | Investing - U.S News & World Report Money
Tag: Cover Crops market in Key Countries - IndiaPolitics.com
Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. and Yield10 Oilseeds, Inc. for $5 million. - Marketscreener.com
Yield10 Bioscience Announces Asset Sale and Planned Dissolution - TipRanks
Biodegradable Polymers Global Market Overview 2021-2023 & Forecasts 2024-2030 - GlobeNewswire
5 Best-Performing Biotech Stocks for October 2024 - NerdWallet
6 Best Health Care ETFs to Buy Now | Investing - U.S News & World Report Money
Twist Bioscience executive sells over $10k in company stock - Investing.com India
Ypsomed reports positive automated insulin pump outcomes - Drug Delivery Business News
In the Green: Relay Therapeutics Inc (RLAY) Closes at 7.50, Up/Down -4.58 from Previous Day - The Dwinnex
Solar91 Cleantech files draft papers to raise Rs 100 cr via SME IPO - NewsDrum
Wave Life Sciences gains as B. Riley issues buy on RNS editing tech - MSN
Early Revolut & Canva investor backs Yonder in £23.4m round - BusinessCloud
Yonder secures £23.4m in funding led by Revolut investor to fuel global expansion - Business Live
XTX Topco Ltd Buys 19,604 Shares of DoorDash, Inc. (NASDAQ:DASH) - MarketBeat
Arizona State Retirement System Has $109,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Yonder Technology (t/a Yonder) secures £23.4 million Series B Investment led by Repeat - UK Tech Investment News
Parse Biosciences scores victory in patent dispute - The Business Journals
The Digest’s 2024 Multi-Slide Guide to Yield10 Biosciences, the investment perspective - Biofuels Digest
BCRX: 3 High-Potential Biotech Stocks Under $10 - StockNews.com
Stock market today: Stocks rise as Powell declares 'time has come' to begin cutting interest rates - Yahoo Finance
Yield10 Finalizes Nufarm License for Key Omega-3 Asset - ChemAnalyst
9 Short Squeeze Stocks That Could Take Off | Investing - U.S News & World Report Money
Yield10 grants Nufarm license to certain Omega-3 intellectual property asset - Indian Chemical News
Yield10 Bioscience signs MOU and licensing agreement with Nuseed for omega-3 assets - Oils & Fats International
Yield10 Bioscience Announces Second Quarter 2024 Financial Results - StockTitan
South Dakota Public Utilities Commission fines oilseed buyer $15,000 in civil penalties - Mitchell Republic
Yield10 Bioscience grants Nufarm commercial license to produce omega-3 oil - Aquafeed.com
Yield10 Bioscience Settles Convertible Note Early for $500K - TipRanks
Cover Crops Market Size, Share, Growth Drivers, and Forecast - MarketsandMarkets
CRISPR in Agriculture Market Growth Report |Arcadia Biosciences, Bayer AG, BASF SE, Beam Therapeutics Inc., Benson Hill – Moose Gazette - Moose Gazette
Metabolix announces strategic restructuring - Reuters.com
SD PUC fines Massachusetts-based company $15,000 - KELOLAND.com
Ag-tech company Nufarm, with lab in West Sac, to buy omega-3 oils producing assets for up to $5 million - The Business Journals
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets - The Korea Bizwire
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and… - Informazione.it
Yield10 Bioscience Grants Nufarm a Commercial License to - GlobeNewswire
Delisting of Securities of CONX Corp.; Priveterra Acquisition Corp. II; Yield10 Bioscience, Inc.; Aesthetic Medical International Holdings Group Ltd.; Breeze Holdings Acquisition Corp.; Quadro Acquisition One Corp.; DermTech, Inc.; TRACON Pharmaceuticals, I - StockTitan
Yield 10 Bioscience Inc (YTEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
8.99%
자본화:
|
볼륨(24시간):